Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $79.55 USD
Change Today -3.18 / -3.84%
Volume 792.0
SHPGF On Other Exchanges
SHPGF is not on other exchanges.
As of 8:10 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

shire plc (SHPGF) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/29/14 - $87.45
52 Week Low
10/15/14 - $52.99
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SHIRE PLC (SHPGF)

shire plc (SHPGF) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides BUCCOLAM for epilepsy treatment; PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist that is used for the treatment of chronic constipation in women. In addition, it offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR and CINRYZE C1 esterase inhibitor for the treatment of hereditary angioedema. Further, the company provides FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; XAGRID that is used for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients; and PLENADREN for the treatment of adrenal insufficiency. Additionally, it licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. The company also focuses on the development of resources projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology, and gastrointestinal disorders; and early development projects primarily on rare diseases. Shire plc markets its products through wholesalers and pharmacies. The company has research collaboration with ArmaGen Technologies Inc., Santaris Pharma A/S, and Sangamo. Shire plc was founded in 1986 and is based in Dublin, Ireland.

5,016 Employees
Last Reported Date: 02/24/15
Founded in 1986

shire plc (SHPGF) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $3.6M
Compensation as of Fiscal Year 2014.

shire plc (SHPGF) Key Developments

Shire plc Announces Executive Appointments

Shire plc announced the appointment of Bill Mordan as General Counsel and Corporate Secretary, reporting to CEO Flemming Ornskov. Bill will also serve as a member of the company Executive Committee. He joins the company from Reckitt Benckiser Group plc where he served as Group General Counsel and Corporate Secretary. Bill will join the company following a notice period at Reckitt Benckiser. Bill joined Reckett Benckiser in 2003 as Area Vice President, North America. From 1997 to 2003, he worked for Procter & Gamble, holding diverse legal positions in Brazil, Mexico and the company's corporate headquarters in Cincinnati, Ohio. Earlier in his career, Bill served as a law clerk in the U.S. Court of Appeals for the Sixth Circuit and taught high school in Bolivia. The company also announced the appointment of Michele Galen as Head of Corporate Communications and Public Affairs, reporting to Flemming Ornskov. Michele will also serve as an extended member of the company Executive Committee. A lawyer and journalist, Michele most recently served as a Managing Director for MPM Capital and corporate advisor. From 2001-2014, Michele worked at Novartis in diverse leadership roles, including as the company's Chief Communications Officer, based in Basel, Switzerland. Earlier, she worked as Managing Director for Burson-Marsteller, Editor for Business Week, and as an associate for Skadden, Arps, Slate, Meagher & Flom. Both the General Counsel and Communications roles will be based at the company's headquarters in Lexington, Massachusetts.

Shire plc Presents at BIO International Convention 2015, Jun-17-2015 10:30 AM

Shire plc Presents at BIO International Convention 2015, Jun-17-2015 10:30 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States.

Shire plc Names Olivier Bohuon as Non-Executive Director and Member of the Science & Technology Committee of the Company Board

Shire plc announced the appointment of Olivier Bohuon to the company’s board of directors as a non-executive director. Olivier will also be a member of the Science & Technology Committee of the company board. Both appointments will be effective from July 1, 2015. Olivier has served as chief executive officer of Smith & Nephew plc since 2011. He has extensive international business and leadership experience across a number of pharmaceutical and healthcare companies in Europe, the Middle East and U.S. He also serves as a non-executive director of Virbac Group SA. Olivier is a member of the Smith & Nephew plc Board of Directors, where he also serves on the Nomination & Governance Committee. Prior to Smith & Nephew, Olivier served as the Chief Executive Officer and President of Pierre Fabre Group, and as President of Abbott Pharmaceuticals, a division of Abbott Corporation based in the U.S. He has also held diverse commercial leadership positions for GlaxoSmithKline and its predecessor companies in France.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPGF:US $79.55 USD -3.18

SHPGF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CSL Ltd A$87.56 AUD +1.09
Eisai Co Ltd ¥8,170 JPY -46.00
Hospira Inc $88.71 USD +0.02
Mylan NV $67.86 USD +0.23
Perrigo Co PLC $184.83 USD +0.69
View Industry Companies

Industry Analysis


Industry Average

Valuation SHPGF Industry Range
Price/Earnings 13.9x
Price/Sales 7.7x
Price/Book 5.3x
Price/Cash Flow 13.4x
TEV/Sales 7.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at